S-1/A: Lakewood-Amedex plans Nasdaq direct listing

Lakewood-Amedex Biotherapeutics seeks a Nasdaq direct listing with a concurrent $7.5m Series C preferred financing and aims to start a Phase 2a trial for lead anti-infective Nu-3.

Summary

• Pursues a direct listing on Nasdaq Capital Market (ticker: LABT) via resale of up to 4,689,177 existing common shares; no primary proceeds to the company.
• Engaged RBW Capital Partners as financial advisor for the direct listing and placement agent (with Dawson James) for a $7.5m private placement of Series C Preferred Stock at $10.00 per share, subject to a 20% discount and a $1.00 conversion floor.
• Series C Preferred is convertible into common at the lower of $10.00 or 80% of the 5-day average closing price (floor $1.00), with 9.6% annual cumulative dividends (cash or PIK) starting six months post-listing and a 4.99% conversion blocker.
• Committed to file a resale registration statement for the Series C conversion shares and advisory shares within 10 days after the common stock lists on Nasdaq.
• RBW to receive 269,411 advisory shares (1.75% of current fully diluted) as compensation; advisory shares are not covered by this registration.
• Clinical focus: Nu-3 (topical bisphosphocin) for mildly infected diabetic foot ulcers; Phase 2a single-blind, open-label study planned immediately after receipt of Series C funds and listing, followed by a Phase 2b placebo-controlled study already discussed with FDA.
• Pipeline includes preclinical bisphosphocin candidates (Nu-8, Nu-10, Nu-11) targeting CAUTI and pulmonary infections; large-animal toxicology established a high NOAEL supporting higher gel concentrations.
• Financials (nine months ended Sept 30, 2025): revenue $0; net loss $3.10m; R&D $1.07m; G&A $1.99m; cash $0.66m; total liabilities $2.25m; stockholders’ equity (deficit) $(1.27)m; cash used in operations $(1.52)m.
• Raised $1.5m in 10% convertible notes in May 2025 (auto-convert at $8.00/share upon listing; maturity extended to Mar 31, 2026).
• Auditor issued a going-concern emphasis; business model and clinical progress remain dependent on additional capital and successful listing approval by Nasdaq.

Sentiment

Score: 4

Explanation: StockSavvy.ai views the strategy as scientifically differentiated but notes elevated financing, dilution, and execution risk given the going-concern disclosure, prior fraud loss, contingent listing, and variable-price preferred terms.

Positives

• Clear direct listing pathway on Nasdaq with an experienced advisor (RBW) and defined opening price discovery process.
• $7.5m Series C Preferred financing committed, providing near-term capital to fund the Nu-3 Phase 2a study.
• Lead asset Nu-3 has supportive exploratory Phase 1/2a signals and a completed large-animal toxicology study establishing a high NOAEL for up to two weeks of dosing.
• Robust IP estate with 68 issued and 36 pending patents as of January 2026 (coverage across key markets).
• Preclinical data show broad-spectrum activity and potential low resistance emergence; local delivery could reduce systemic side effects.
• Convertible notes of $1.5m provide bridge liquidity before listing; automatic conversion at $8.00/share upon listing reduces cash repayment risk.

Negatives

• No revenue and continuing operating losses (net loss of $3.10m for the nine months ended Sept 30, 2025) with a stockholders’ deficit of $(1.27)m and cash of only $0.66m at Sept 30, 2025.
• Going-concern uncertainty disclosed by the independent auditor.
• Prior $1.04m fraud-related loss recognized in 2024 underscores operational and control risks.
• Series C Preferred includes variable price conversion (down to $1.00 floor) and 9.6% cumulative dividends, creating meaningful potential dilution and cash/PIK obligations.
• Listing is contingent on Nasdaq approval; failure to list terminates the direct listing plan.
• Direct listing (no underwriter) can increase initial trading volatility and lacks traditional book-building support.

Risks

• Nasdaq listing approval is uncertain; the direct listing will not proceed without approval and listing is a condition of the offering.
• Significant dilution risk from Series C Preferred’s variable conversion price (80% VWAP with $1.00 floor) and cumulative 9.6% dividend.
• Auditor’s going-concern emphasis and limited cash increase financing and continuity risk.
• Clinical and regulatory risk remains high; a 2022 Phase 2 study was halted pending additional toxicology, and future studies depend on FDA and foreign regulatory outcomes.
• Reliance on CROs, CDMOs, and third parties for trials and manufacturing introduces execution and compliance risks.
• Manufacturing scale-up and stability for antimicrobial products are complex and subject to cGMP and supply-chain constraints.
• Potential market access and reimbursement challenges for new antimicrobials could limit commercial uptake even if approved.
• Direct listing structure can result in heightened price volatility and uncertain trading volume without an underwriter’s stabilization.
• Large number of registered shares (4,689,177) and potential future resales (including for Series C conversion) may pressure the stock.
• Cybersecurity and operational risks highlighted by a prior fraud loss and general data security exposures.

Future Outlook

Plans to commence a Phase 2a open-label Nu-3 gel study immediately after the Series C financing and Nasdaq listing, followed by a Phase 2b double-blind, placebo-controlled trial agreed in principle with FDA; aims to advance CAUTI and pulmonary candidates (Nu-8, Nu-10, Nu-11) toward IND-enabling work while pursuing Nasdaq listing under LABT and registering the Series C and advisory shares within 10 days of listing.

Management Comments

• Intends to initiate a Phase 2a safety and dose-response study of Nu-3 gel in mildly infected diabetic foot ulcers immediately after receiving Series C investment and listing on Nasdaq.
• Plans to follow Phase 2a with a placebo-controlled Phase 2b dose-comparative study to identify the optimal dose and regimen for Phase 3 and commercialization.
• Expects the Series C proceeds to fund completion of the Phase 2a study.
• Aims to progress additional bisphosphocin candidates for CAUTI and pulmonary infections through non-clinical profiling and into clinical development upon IND acceptance.

Industry Context

StockSavvy.ai notes antimicrobial resistance remains a critical global health challenge with limited novel mechanisms reaching late stage; many antibiotic pipelines focus on established classes and systemic therapies. Lakewood-Amedex targets a differentiated niche with local delivery and a new class (bisphosphocins), competing against early-stage topical competitors such as Recce 327 and pravibismane and facing an industry backdrop marked by mixed commercial outcomes (e.g., prior setbacks at Achaogen, consolidation at Paratek) and heightened payer scrutiny.

Comparison to Industry Standards

• Compared to systemic antibiotic developers (e.g., Spero Therapeutics’ tebipenem pivoxil HBr program), Lakewood-Amedex focuses on local delivery to infection sites, which may reduce systemic toxicity and alter regulatory and PK requirements.
• Relative to topical competitors (e.g., Recce 327 and Microbion’s pravibismane), Nu-3 emphasizes gel formulation for iDFU with a Phase 2 program aligned with FDA feedback and preclinical NOAEL support in large animals.
• Against broader anti-infective peers (e.g., SCYNEXIS in antifungals), the business model faces similar reimbursement constraints but could benefit from localized delivery economics and a broader AMR narrative.
• Financing scale ($7.5m Series C plus $1.5m notes) is smaller than typical Phase 2 systemic antibiotic programs, implying tight capital discipline and staged clinical execution relative to industry norms.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings disclosed.

Related Party Transactions

• May 2025: Convertible notes totaling $1.5m included participations by insiders (e.g., Doug Manion $50k, Leonard DeRoma $5k, Peter Ceccacci $25k, the late Charles Wright $300k).
• June 2024: Conversion of $200,000 related-party notes (Lindesfarne LLC) into 56,307 common shares; $143,020 accrued interest forgiven and recorded as capital contribution.

Stakeholder Impact

• Common shareholders face potential dilution from Series C Preferred’s variable-price conversion and 9.6% dividends.
• Employees and management gain equity-based incentives but must operate under going-concern constraints and tight budgets until capital closes.
• Clinical trial partners (CROs/CDMOs) depend on timely financing to proceed with Phase 2a/2b and IND-enabling work.
• Preferred investors benefit from downside protection (variable conversion with floor) and cumulative dividends, prioritizing returns ahead of common equity.
• Creditors and vendors face counterparty risk given limited cash and going-concern uncertainty.

Next Steps

• Secure Nasdaq approval for the direct listing (LABT).
• Close the $7.5m Series C Preferred financing prior to listing.
• File resale registration for Series C conversion and advisory shares within 10 days post-listing.
• Initiate the Phase 2a open-label Nu-3 gel study; subsequently execute the Phase 2b double-blind, placebo-controlled trial.
• Advance bisphosphocin pipeline candidates (Nu-8, Nu-10, Nu-11) toward INDs for CAUTI and pulmonary indications.

Key Dates

Recommendation

For existing holders, the differentiated science and near-term Phase 2a catalyst are balanced by listing uncertainty, going-concern risk, and material dilution from the variable-price preferred; awaiting listing, financing close, and Phase 2a initiation data justifies a neutral stance.

Keywords

direct listing, bisphosphocin, antimicrobial resistance, Nu-3, diabetic foot ulcer, Series C Preferred, convertible notes, Nasdaq Capital Market, RBW Capital Partners, Dawson James, clinical Phase 2a, CAUTI, pulmonary infections, going concern, biotech financing